Norway· NO-ID_F58D326E-161B-4E12-AFA0-C2236EE98973
Vitrakvi
A larotrectinib product containing larotrectinib, registered in Norway by Bayer AG. The same ATC class is registered in 13 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Larotrectinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01EX12 (larotrectinib), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Larotrectinib · ATC L01EX12
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of larotrectinib costs, country by country.
Normalised to the WHO defined daily dose (0.2 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Larotrectinib · price per daily dose (0.2 g)
USD · FX 28 Sept 2026
- CH Switzerland$254.41
The record
At a glance
FEST (Norway)- Active substance
- Larotrectinib
- Manufacturer
- Bayer AG
- Country
- Norway (NO)
- ATC code
- L01EX12
- ATC class
- Larotrectinib
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_F58D326E-161B-4E12-AFA0-C2236EE98973
- no_varenummer3802772 x 50NOK 23188.4
- gtin4057598012300
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
527 interactions on record for larotrectinib.
Graded by severity as the source publishes them — 55 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Larotrectinib · interactions on record
527 records
- 55 severe
- 456 moderate
- 16 minor
Most severe, free to view
- LonafarnibA16AX20severe
- ConivaptanC03XA02severe
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Larotrectinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainVITRAKVI 20 MG/ML SOLUCION ORAL, 1 frasco de 100 mlBayer Ag
- SwedenVITRAKVI 20 mg/ml (1000 mg/50 ml) Oral lösningBayer AG
- BelgiumVitrakvi 20 mg/mlBayer
- FranceVITRAKVI 20 mg/mL, solution buvableBAYER AG (ALLEMAGNE)
- IrelandVITRAKVI 20 mg/ml Oral solutionBayer AG
- IcelandVITRAKVIBayer AG
- NetherlandsVitrakvi 20 mg/ml, drankBayer AG
- PolandVitrakviBayer AG
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Vitrakvi
- Liechtenstein · Vitrakvi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a0329c14-c7de-4b78-a78b-bcdda8f8328a GET /v1/drugs/a0329c14-c7de-4b78-a78b-bcdda8f8328a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Mikstur, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Larotrektinib",
"merkevare_id": "ID_F58D326E-161B-4E12-AFA0-C2236EE98973",
"name_form_strength": "Vitrakvi mikst oppl 20 mg/ml",
"prescription_group": "C"
}See everything about larotrectinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.